Iron ion and siramesine-loaded polydopamine nanoparticles forenhanced breast cancer therapy
DOI:
https://doi.org/10.61173/xr68nm90Keywords:
Ferroptosis, Siramesine, Polydopamine, Ferroportin, Breast cancer therapyAbstract
Ferroptosis is a novel type of nonapoptotic cell death, showing a hopeful potential in cancer therapeutic schedules. One
of the apparent features of ferroptosis is the lipid hydroperoxides producing ROS induced by intracellular iron ions
accumulation. Thus the iron regulation and metabolism in the cell is an essential factors for the trigger of ferroptosis.
We designed a new nanoparticle that loaded ferric ions and siamese based on polydopamine nanomaterial (siramesine@
Fe(III) PDA NPs) to induce breast cancer ferroptosis through the Fenton reaction. Iron ions can be added to cancer cells,
and siamese can block the exportation of intracellular iron by inhibiting the expression of FPN, thus promoting the
Fenton reaction. The extra transport of iron ions into cells by nanoparticles and the inhibition of iron ions outward by
Siramesine promoted the accumulation of iron ions in cells, thus achieving a synergistic effect leading to ferroptosis in
cells. In addition, NPs demonstrated excellent pH-responsive degradation, with enhanced drug release at the pH value
of tumor microenvironments and lysosomal. Siramesine@Fe(III) PDA NPs showed good ferroptosis induction ability,
displaying the potential for cancer treatment.
References
[1] Waks, A. G.; Winer, E. P. Breast Cancer Treatment: A Review. JAMA 2019, 321 (3), 288–300. https://doi.org/10.1001/ jama.2018.19323.
[2] Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021, 71 (3), 209–249. https://doi.org/10.3322/caac.21660.
[3] Liu, J.; Shen, J.-X.; Wen, X.-F.; Guo, Y.-X.; Zhang, G.- J. Targeting Notch Degradation System Provides Promise for Breast Cancer Therapeutics. Crit. Rev. Oncol. Hematol. 2016, 104, 21–29. https://doi.org/10.1016/j.critrevonc.2016.05.010.
[4] Ono, M.; Ogilvie, J. M.; Wilson, J. S.; Green, H. J.; Chambers, S. K.; Ownsworth, T.; Shum, D. H. K. A Meta- Analysis of Cognitive Impairment and Decline Associated with Adjuvant Chemotherapy in Women with Breast Cancer. Front. Oncol. 2015, 5, 59. https://doi.org/10.3389/fonc.2015.00059.
[5] Shapiro, C. L.; Recht, A. Side Effects of Adjuvant Treatment of Breast Cancer. N. Engl. J. Med. 2001, 344 (26), 1997–2008. https://doi.org/10.1056/NEJM200106283442607.
[6] Saeki, T.; Tsuruo, T.; Sato, W.; Nishikawsa, K. Drug Resistance in Chemotherapy for Breast Cancer. Cancer Chemother. Pharmacol. 2005, 56 (1), 84–89. https://doi. org/10.1007/s00280-005-0106-4.
[7] Musgrove, E. A.; Sutherland, R. L. Biological Determinants of Endocrine Resistance in Breast Cancer. Nat. Rev. Cancer 2009, 9 (9), 631–643. https://doi.org/10.1038/nrc2713.
[8] El Ansari, R.; McIntyre, A.; Craze, M. L.; Ellis, I. O.; Rakha, E. A.; Green, A. R. Altered Glutamine Metabolism in Breast Cancer; Subtype Dependencies and Alternative Adaptations. Histopathology 2018, 72 (2), 183–190. https://doi.org/10.1111/ his.13334.
[9] Carneiro, B. A.; El-Deiry, W. S. Targeting Apoptosis in Cancer Therapy. Nat. Rev. Clin. Oncol. 2020, 17 (7), 395–417. https://doi.org/10.1038/s41571-020-0341-y.
[10] Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The next Generation. Cell 2011, 144 (5), 646–674. https://doi. org/10.1016/j.cell.2011.02.013.
[11] Dixon, S. J.; Lemberg, K. M.; Lamprecht, M. R.; Skouta, R.; Zaitsev, E. M.; Gleason, C. E.; Patel, D. N.; Bauer, A. J.; Cantley, A. M.; Yang, W. S.; Morrison, B.; Stockwell, B. R. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell 2012, 149 (5), 1060–1072. https://doi.org/10.1016/ j.cell.2012.03.042.
[12] Stockwell, B. R.; Friedmann Angeli, J. P.; Bayir, H.; Bush, A. Dean&Francis I.; Conrad, M.; Dixon, S. J.; Fulda, S.; Gascón, S.; Hatzios, S. K.; Kagan, V. E.; Noel, K.; Jiang, X.; Linkermann, A.; Murphy, M. E.; Overholtzer, M.; Oyagi, A.; Pagnussat, G. C.; Park, J.; Ran, Q.; Rosenfeld, C. S.; Salnikow, K.; Tang, D.; Torti, F. M.; Torti, S. V.; Toyokuni, S.; Woerpel, K. A.; Zhang, D. D. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017, 171 (2), 273–285. https://doi. org/10.1016/j.cell.2017.09.021.
[13] Xie, Y.; Hou, W.; Song, X.; Yu, Y.; Huang, J.; Sun, X.; Kang, R.; Tang, D. Ferroptosis: Process and Function. Cell Death Differ. 2016, 23 (3), 369–379. https://doi.org/10.1038/ cdd.2015.158.
[14] Yang, W. S.; SriRamaratnam, R.; Welsch, M. E.; Shimada, K.; Skouta, R.; Viswanathan, V. S.; Cheah, J. H.; Clemons, P. A.; Shamji, A. F.; Clish, C. B.; Brown, L. M.; Girotti, A. W.; Cornish, V. W.; Schreiber, S. L.; Stockwell, B. R. Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell 2014, 156 (1), 317–331. https://doi.org/10.1016/j.cell.2013.12.010.
[15] Angeli, J. P. F.; Shah, R.; Pratt, D. A.; Conrad, M. Ferroptosis Inhibition: Mechanisms and Opportunities. Trends Pharmacol. Sci. 2017, 38 (5), 489–498. https://doi.org/10.1016/ j.tips.2017.02.005.
[16] Banjac, A.; Perisic, T.; Sato, H.; Seiler, A.; Bannai, S.; Weiss, N.; Kölle, P.; Tschoep, K.; Issels, R. D.; Daniel, P. T.; Conrad, M.; Bornkamm, G. W. The Cystine/Cysteine Cycle: A Redox Cycle Regulating Susceptibility versus Resistance to Cell Death. Oncogene 2008, 27 (11), 1618–1628. https://doi. org/10.1038/sj.onc.1210796.
[17] Ray, P. D.; Huang, B.-W.; Tsuji, Y. Reactive Oxygen Species (ROS) Homeostasis and Redox Regulation in Cellular Signaling. Cell. Signal. 2012, 24 (5), 981–990. https://doi. org/10.1016/j.cellsig.2012.01.008.
[18] Bystrom, L. M.; Guzman, M. L.; Rivella, S. Iron and Reactive Oxygen Species: Friends or Foes of Cancer Cells? Antioxid. Redox Signal. 2014, 20 (12), 1917–1924. https://doi. org/10.1089/ars.2012.5014.
[19] Conrad, M.; Pratt, D. A. The Chemical Basis of Ferroptosis. Nat. Chem. Biol. 2019, 15 (12), 1137–1147. https://doi. org/10.1038/s41589-019-0408-1.
[20] Yang, W. S.; Stockwell, B. R. Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol. 2016, 26 (3), 165–176. https:// doi.org/10.1016/j.tcb.2015.10.014.
[21] Hassannia, B.; Vandenabeele, P.; Vanden Berghe, T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell 2019, 35 (6), 830–849. https://doi.org/10.1016/j.ccell.2019.04.002.
[22] Dixon, S. J.; Stockwell, B. R. The Role of Iron and Reactive Oxygen Species in Cell Death. Nat. Chem. Biol. 2014, 10 (1), 9–17. https://doi.org/10.1038/nchembio.1416.
[23] Bogdan, A. R.; Miyazawa, M.; Hashimoto, K.; Tsuji, Y. Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease. Trends Biochem. Sci. 2016, 41 (3), 274–286. https://doi.org/10.1016/j.tibs.2015.11.012.
[24] Liu, X.-B.; Yang, F.; Haile, D. J. Functional Consequences of Ferroportin 1 Mutations. Blood Cells. Mol. Dis. 2005, 35 (1), 33–46. https://doi.org/10.1016/j.bcmd.2005.04.005.
[25] Nemeth, E.; Tuttle, M. S.; Powelson, J.; Vaughn, M. B.; Donovan, A.; Ward, D. M.; Ganz, T.; Kaplan, J. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science 2004, 306 (5704), 2090– 2093. https://doi.org/10.1126/science.1104742.
[26] Donovan, A.; Lima, C. A.; Pinkus, J. L.; Pinkus, G. S.; Zon, L. I.; Robine, S.; Andrews, N. C. The Iron Exporter Ferroportin/ Slc40a1 Is Essential for Iron Homeostasis. Cell Metab. 2005, 1 (3), 191–200. https://doi.org/10.1016/j.cmet.2005.01.003.
[27] De Domenico, I.; Ward, D. M.; Nemeth, E.; Vaughn, M. B.; Musci, G.; Ganz, T.; Kaplan, J. The Molecular Basis of Ferroportin-Linked Hemochromatosis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102 (25), 8955–8960. https://doi.org/10.1073/ pnas.0503804102.
[28] Schimanski, L. M.; Drakesmith, H.; Merryweather-Clarke, A. T.; Viprakasit, V.; Edwards, J. P.; Sweetland, E.; Bastin, J. M.; Cowley, D.; Chinthammitr, Y.; Robson, K. J. H.; Townsend, A. R. M. In Vitro Functional Analysis of Human Ferroportin (FPN) and Hemochromatosis-Associated FPN Mutations. Blood 2005, 105 (10), 4096–4102. https://doi.org/10.1182/ blood-2004-11-4502.
[29] Pelucchi, S.; Mariani, R.; Salvioni, A.; Bonfadini, S.; Riva, A.; Bertola, F.; Trombini, P.; Piperno, A. Novel Mutations of the Ferroportin Gene (SLC40A1): Analysis of 56 Consecutive Patients with Unexplained Iron Overload. Clin. Genet. 2008, 73 (2), 171–178. https://doi.org/10.1111/j.1399-0004.2007.00950.x.
[30] Ma, S.; Dielschneider, R. F.; Henson, E. S.; Xiao, W.; Choquette, T. R.; Blankstein, A. R.; Chen, Y.; Gibson, S. B. Ferroptosis and Autophagy Induced Cell Death Occur Independently after Siramesine and Lapatinib Treatment in Breast Cancer Cells. PloS One 2017, 12 (8), e0182921. https:// doi.org/10.1371/journal.pone.0182921.
[31] Geng, N.; Zhou, H. Knockdown of Ferroportin Accelerates Erastin-Induced Ferroptosis in Neuroblastoma Cells. 11.
[32] Namgaladze, D.; Fuhrmann, D. C.; Brüne, B. Interplay of Nrf2 and BACH1 in Inducing Ferroportin Expression and Enhancing Resistance of Human Macrophages towards Ferroptosis. Cell Death Discov. 2022, 8 (1), 327. https://doi. org/10.1038/s41420-022-01117-y.
[33] Laskar, A.; Ghosh, M.; Khattak, S. I.; Li, W.; Yuan, X.-M. Degradation of Superparamagnetic Iron Oxide Nanoparticle- Induced Ferritin by Lysosomal Cathepsins and Related Immune Response. Nanomed. 2012, 7 (5), 705–717. https://doi. org/10.2217/nnm.11.148.
[34] Boya, P.; Kroemer, G. Lysosomal Membrane Permeabilization in Cell Death. Oncogene 2008, 27 (50), 6434– 6451. https://doi.org/10.1038/onc.2008.310.
[35] Ma, S.; Henson, E. S.; Chen, Y.; Gibson, S. B. Ferroptosis Is Induced Following Siramesine and Lapatinib Treatment of Dean&Francis Breast Cancer Cells. Cell Death Dis. 2016, 7, e2307. https://doi. org/10.1038/cddis.2016.208.
[36] Liu, M.; Liu, B.; Liu, Q.; Du, K.; Wang, Z.; He, N. Nanomaterial-Induced Ferroptosis for Cancer Specific Therapy. Coord. Chem. Rev. 2019, 382, 160–180. https://doi.org/10.1016/ j.ccr.2018.12.015.
[37] Ma, P.; Xiao, H.; Yu, C.; Liu, J.; Cheng, Z.; Song, H.; Zhang, X.; Li, C.; Wang, J.; Gu, Z.; Lin, J. Enhanced Cisplatin Chemotherapy by Iron Oxide Nanocarrier-Mediated Generation of Highly Toxic Reactive Oxygen Species. Nano Lett. 2017, 17 (2), 928–937. https://doi.org/10.1021/acs.nanolett.6b04269.
[38] Liu, X.; Cao, J.; Li, H.; Li, J.; Jin, Q.; Ren, K.; Ji, J. Mussel- Inspired Polydopamine: A Biocompatible and Ultrastable Coating for Nanoparticles in Vivo. ACS Nano 2013, 7 (10), 9384–9395. https://doi.org/10.1021/nn404117j.
[39] Farokhi, M.; Mottaghitalab, F.; Saeb, M. R.; Thomas, S. Functionalized Theranostic Nanocarriers with Bio-Inspired Polydopamine for Tumor Imaging and Chemo-Photothermal Therapy. J. Controlled Release 2019, 309, 203–219. https://doi. org/10.1016/j.jconrel.2019.07.036.
[40] Li, H.; Yin, D.; Li, W.; Tang, Q.; Zou, L.; Peng, Q. Polydopamine-Based Nanomaterials and Their Potentials in Advanced Drug Delivery and Therapy. Colloids Surf. B Biointerfaces 2021, 199, 111502. https://doi.org/10.1016/ j.colsurfb.2020.111502.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
